Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Minden

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Blood Cancer Journal|May 28, 2013
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogeneticsJ How, J Sykes, M D Minden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?N Timilshina, H Breunis, J M Brandwein, et al.
Leukemia|January 26, 2007
A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for responseJ M Brandwein, L Yang, A D Schimmer, et al.
Bone Marrow Transplantation|June 1, 1997
Quality of life following bone marrow transplantation: a comparison of patient reports with population normsH J Sutherland, G M Fyles, G Adams, et al.
Bone Marrow Transplantation|December 1, 1991
Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rateG M Fyles, H A Messner, G Lockwood, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1986
Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemiaE A Shima, M M Le Beau, T W McKeithan, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical PracticeJ. E. Curtis, Y. Hao, H. A. Messner, et al.
Leukemia|March 16, 2011
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete responseJ M Brandwein, D W Hedley, S Chow, et al.
Blood|August 1, 1989
A possible autocrine role for interleukin-6 in two lymphoma cell linesC Yee, A Biondi, X H Wang, et al.
Leukemia|December 19, 2008
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and overJ M Brandwein, B F Leber, K Howson-Jan, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|May 28, 2013
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogeneticsJ How, J Sykes, M D Minden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?N Timilshina, H Breunis, J M Brandwein, et al.
Leukemia|January 26, 2007
A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for responseJ M Brandwein, L Yang, A D Schimmer, et al.
Bone Marrow Transplantation|June 1, 1997
Quality of life following bone marrow transplantation: a comparison of patient reports with population normsH J Sutherland, G M Fyles, G Adams, et al.
Bone Marrow Transplantation|December 1, 1991
Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rateG M Fyles, H A Messner, G Lockwood, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1986
Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemiaE A Shima, M M Le Beau, T W McKeithan, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical PracticeJ. E. Curtis, Y. Hao, H. A. Messner, et al.
Leukemia|March 16, 2011
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete responseJ M Brandwein, D W Hedley, S Chow, et al.
Blood|August 1, 1989
A possible autocrine role for interleukin-6 in two lymphoma cell linesC Yee, A Biondi, X H Wang, et al.
Leukemia|December 19, 2008
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and overJ M Brandwein, B F Leber, K Howson-Jan, et al.
Pageof 15